Purpose

Study to test the hypothesis that aerosolized Infasurf can decrease the need for intubation and instillation of liquid surfactant to the airway.

Condition

Eligibility

Eligible Ages
Between 1 Hour and 24 Hours
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

RDS Patients 1. NICU patient, ≥1hour of age and <24 hours of age. 2. Clinical diagnosis of RDS, with or without chest X-ray data. 3. Inspired oxygen ≥21% to maintain adequate oxygen saturation. 4. Not intubated 5. Requiring: 1. nasal continuous positive airway pressure (nCPAP).

Exclusion Criteria

  1. Congenital anomaly limiting care options or requiring early surgery. 2. Cardiopulmonary decompensation. 1. hypotension with metabolic acidosis (base excess < -10 meq/l). 2. Oxygen saturations < 88% at start of aerosolization. 3. PaCO2 ≥ 60 mmHg at start of aerosolization. 3. Grade 3 or Grade 4 intraventricular hemorrhage by cranial ultrasound, if known. 4. Acute hypoxic encephalopathy with or without seizures.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Aerosolized Calfactant
NICU Patients with a clinical diagnosis of RDS Inspired oxygen ≥21% to maintain adequate oxygen saturation Not Intubated Requiring Nasal continuous positive airway pressure
  • Drug: Aerosolized Calfactant
    Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
    Other names:
    • Infasurf
    • Calfactant
  • Device: Solarys
    Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
No Intervention
Usual Care
There will be no protocol driven interventions in the usual care group.

More Details

Status
Completed
Sponsor
ONY

Study Contact

Detailed Description

Treatment will not be masked. The study objective is to document that aerosolized Infasurf is superior to "usual care" and provides for some patients effective surfactant therapy with less need for endotracheal intubation and instillation of a surfactant suspension into the airway. Two cohorts will be recruited: (a) patients who did not receive surfactant at birth who develop RDS in the first hours of life and (b) patients who received instillation of surfactant for RDS in the first hour of life, were extubated, and have continuing RDS.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.